Lipid lowering in patients with treatment-resistant hypertension: An analysis from the Treating to New Targets (TNT) trial

European Heart Journal

Volumn 35, Issue 27, 2014, Pages 1801-1808

  Bangalore, Sripal ^a   Fayyad, Rana ^b   Laskey, Rachel ^b   Demicco, David ^b   Deedwania, Prakash ^c   Kostis, John B ^d   Messerli, Franz H ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e St Luke's Roosevelt Hospital Columbia University College of Physicians and Surgns ^*  (United States)

Author keywords

Intensive; Lipid lowering; Outcome; Resistant hypertension; Standard

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; HEART ARREST; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MYALGIA; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESISTANT HYPERTENSION; CONTROLLED STUDY; CORONARY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PYRROLES; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84904568050     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht315     Document Type: Article

References (20)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223.
2. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-1964.
3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
4. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-2050.
5. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635-1642.
6. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolledand apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-1058.
7. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-1080.
8. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-e526.
9. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, Caldarella MP, Neri M, Cuccurullo F, Mezzetti A. Cardiovascular outcomein treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005;18:1422-1428.
10. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
11. Grassi G, Seravalle G, Brambilla G, Mancia G. The sympathetic nervous system and new nonpharmacologic approaches to treating hypertension: a focus on renal de-nervation. Can J Cardiol 2012;28:311-317.
12. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376: 1903-1909.
13. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressurein patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;58:765-773.
14. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93:154-158.
15. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvas-tatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, IzzoJL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
17. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001;19:2063-2070.
18. Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens 2007;25:747-750.
19. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25:891-894.
20. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.